NCT01022021View on ClinicalTrials.gov

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2014

Study Completion Date

August 31, 2015

Conditions
Lymphoma
Interventions
DRUG

Rituximab

Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)

DRUG

Bendamustine

Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)

Trial Locations (1)

66205

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

Cephalon
All Listed Sponsors
collaborator

Cephalon

INDUSTRY

lead

University of Kansas Medical Center

OTHER